Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell publishing date : 2021 - 08 - 24 save search
Incyte Announces Health Canada Approval of Minjuvi (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
XNCR | $19.02 3.54% 3.57% 760K
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: -2.7%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 4.43%
H: 0.21%
C: -0.55%
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
|
| O: 0.3%
H: 0.03%
C: -0.29%
canada approval treatment approval t-cell
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
Published: 2021-08-24 (Crawled : 06:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: -1.04%
treatment t-cell
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
HCP | News | $31.41 7.75% 11.26% 1.2M
|
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.